I rate AbbVie stock as a Strong Buy, based on its FDA approval of Rinvoq. Read the latest analysis on the stock here.
Self-administration of rozanolixizumab, a neonatal Fc receptor blocker (FcRn) indicated for generalized myasthenia gravis, ...